#1 Clinical Trials Search in Europe

D-Biotin

This article discusses the use of D-Biotin, a component of the multivitamin drug Cernevit, in clinical trials for patients with cardiogenic shock. The study aims to explore the effects of this multivitamin solution on patients undergoing extracorporeal membrane oxygenation (ECMO) treatment. We’ll examine the trial’s objectives, eligibility criteria, and potential outcomes for patients with severe heart conditions.

Table of Contents

What is D-Biotin?

D-Biotin, also known simply as biotin, is a B-complex vitamin (vitamin B7) that plays a crucial role in various bodily functions[1]. It is an essential nutrient that helps your body convert food into energy and supports the health of your hair, skin, and nails. In the medical context, D-Biotin is often used as part of a multivitamin formulation for patients with specific nutritional needs.

Uses and Benefits

While the primary focus of the clinical trial mentioned in the source document is not on D-Biotin specifically, it is included as part of a multivitamin solution called Cernevit[1]. This medication is being used as a placebo in a study involving patients with cardiogenic shock, a serious condition where the heart cannot pump enough blood to meet the body’s needs.

In general, D-Biotin and other vitamins in such formulations can be beneficial for:

  • Supporting overall nutritional status in critically ill patients
  • Helping the body convert food into energy
  • Maintaining healthy hair, skin, and nails
  • Supporting metabolism of fats and carbohydrates

Administration

According to the information provided, the medication containing D-Biotin (Cernevit) is administered as a solution for injection or infusion[1]. This means it is given directly into the bloodstream, usually in a hospital or clinical setting. The exact dosage and frequency of administration would be determined by healthcare professionals based on the patient’s specific needs.

Other Components in the Medication

It’s important to note that D-Biotin is just one of several vitamins and nutrients included in the Cernevit formulation. Other components include[1]:

  • Retinol Palmitate (a form of Vitamin A)
  • Ascorbic Acid (Vitamin C)
  • Colecalciferol (Vitamin D3)
  • Cyanocobalamin (Vitamin B12)
  • Dexpanthenol (a form of Vitamin B5)
  • Folic Acid (Vitamin B9)
  • Nicotinamide (a form of Vitamin B3)
  • Pyridoxine Hydrochloride (Vitamin B6)
  • Riboflavin Sodium Phosphate (a form of Vitamin B2)
  • DL-Alpha-Tocopherol (Vitamin E)
  • Cocarboxylase Tetrahydrate (a form of Vitamin B1)

This combination of vitamins is designed to provide comprehensive nutritional support for patients who may have difficulty obtaining these nutrients through their regular diet.

Important Considerations

While D-Biotin and the other vitamins in this formulation are generally considered safe, it’s crucial to remember that:

  • This medication should only be administered under medical supervision.
  • It’s typically used in hospital settings for patients with specific medical conditions or nutritional needs.
  • As with any medical treatment, there may be potential side effects or interactions with other medications.
  • The use of this vitamin formulation as a placebo in the mentioned clinical trial does not imply that it treats cardiogenic shock directly.

Always consult with your healthcare provider for personalized medical advice and before starting or changing any treatment regimen.

Aspect Details
Study Drug Cernevit (multivitamin solution containing D-Biotin)
Medical Condition Cardiogenic Shock
Primary Objective Assess efficacy of Levosimendan in improving cardiac output and pulsatile flow
Primary Outcome Change in left ventricular outflow tract velocity time integral
Key Inclusion Criteria Age ≥ 18 years, undergoing ECMO for cardiogenic shock or refractory cardiac arrest
Key Exclusion Criteria Coma with fixed pupil dilation, mechanical cause of shock, onset of shock > 12 hours before screening
Secondary Outcomes Change in pulse pressure, ECMO weaning failure, mortality at 28 days, urinary output, central venous saturation

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to assess the effectiveness of Levosimendan, a drug containing D-Biotin among other vitamins, in improving cardiac output and pulsatile flow for patients on ECMO support due to cardiogenic shock.
  • Who is eligible to participate in this trial? Eligible participants are adults aged 18 years or older who are undergoing ECMO treatment for cardiogenic shock or refractory cardiac arrest.
  • What is ECMO and why is it used in this trial? ECMO stands for Extracorporeal Membrane Oxygenation. It's a life support machine used for patients with severe heart or lung problems. In this trial, it's used to support patients with cardiogenic shock while testing the effects of the multivitamin drug.
  • What are the main outcomes being measured in this study? The primary outcome is the change in left ventricular outflow tract velocity time integral, measured by Doppler echocardiography. Secondary outcomes include changes in pulse pressure, ECMO weaning failure rates, mortality at 28 days, and various other clinical measures.
  • How is D-Biotin involved in this clinical trial? D-Biotin is one of the active substances in Cernevit, the multivitamin solution being studied. While not the primary focus, it's part of the combination of vitamins being investigated for potential benefits in patients with cardiogenic shock.

Ongoing Clinical Trials on D-Biotin

  • Study on the Effects of Levosimendan for Patients with Cardiogenic Shock Being Weaned from ECMO

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria

Glossary

  • Cardiogenic Shock: A serious condition where the heart suddenly can't pump enough blood to meet the body's needs, often due to a severe heart attack.
  • ECMO (Extracorporeal Membrane Oxygenation): A life support machine that pumps and oxygenates a patient's blood outside the body, allowing the heart and lungs to rest.
  • Levosimendan: A medication used to treat acute heart failure by improving the heart's ability to pump blood.
  • D-Biotin: A B-vitamin (also known as vitamin B7) that helps the body convert food into energy and supports various bodily functions.
  • Doppler echocardiography: An ultrasound test that uses sound waves to create images of the heart and measure blood flow through the heart and blood vessels.
  • Pulsatile flow: The normal, rhythmic flow of blood through blood vessels caused by the heart's pumping action.
  • Velocity time integral: A measurement used in echocardiography to assess the amount of blood ejected from the heart with each beat.
  • Central venous saturation: A measure of how much oxygen is in the blood returning to the heart, used to assess how well the body is using oxygen.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-levosimendan-for-patients-with-cardiogenic-shock-being-weaned-from-ecmo/